299 related articles for article (PubMed ID: 34732858)
1. A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation.
Yang M; Pan Z; Huang K; Büsche G; Liu H; Göhring G; Rumpel R; Dittrich-Breiholz O; Talbot S; Scherr M; Chaturvedi A; Eder M; Skokowa J; Zhou J; Welte K; von Neuhoff N; Liu L; Ganser A; Li Z
Leukemia; 2022 Mar; 36(3):675-686. PubMed ID: 34732858
[TBL] [Abstract][Full Text] [Related]
2. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.
Zorko NA; Bernot KM; Whitman SP; Siebenaler RF; Ahmed EH; Marcucci GG; Yanes DA; McConnell KK; Mao C; Kalu C; Zhang X; Jarjoura D; Dorrance AM; Heerema NA; Lee BH; Huang G; Marcucci G; Caligiuri MA
Blood; 2012 Aug; 120(5):1130-6. PubMed ID: 22674806
[TBL] [Abstract][Full Text] [Related]
3. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
[TBL] [Abstract][Full Text] [Related]
5. A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment.
Long J; Chen X; Shen Y; Lei Y; Mu L; Wang Z; Xiang R; Gao W; Wang L; Wang L; Jiang J; Zhang W; Lu H; Dong Y; Ding Y; Zhu H; Hong D; Sun YE; Hu J; Liang A
Cell Rep Med; 2023 Nov; 4(11):101286. PubMed ID: 37951217
[TBL] [Abstract][Full Text] [Related]
6. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
[TBL] [Abstract][Full Text] [Related]
7. Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.
Poitras JL; Heiser D; Li L; Nguyen B; Nagai K; Duffield AS; Gamper C; Small D
Oncotarget; 2016 Oct; 7(43):69124-69135. PubMed ID: 27636998
[TBL] [Abstract][Full Text] [Related]
8. NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.
Rau R; Magoon D; Greenblatt S; Li L; Annesley C; Duffield AS; Huso D; McIntyre E; Clohessy JG; Reschke M; Pandolfi PP; Small D; Brown P
Exp Hematol; 2014 Feb; 42(2):101-13.e5. PubMed ID: 24184354
[TBL] [Abstract][Full Text] [Related]
9. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
[TBL] [Abstract][Full Text] [Related]
10. Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia.
He BL; Yang N; Man CH; Ng NK; Cher CY; Leung HC; Kan LL; Cheng BY; Lam SS; Wang ML; Zhang CX; Kwok H; Cheng G; Sharma R; Ma AC; So CW; Kwong YL; Leung AY
EMBO Mol Med; 2020 Apr; 12(4):e10895. PubMed ID: 32134197
[TBL] [Abstract][Full Text] [Related]
11. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
Elife; 2016 Nov; 5():. PubMed ID: 27879203
[TBL] [Abstract][Full Text] [Related]
12. Cytarabine-Resistant
Ko YC; Hu CY; Liu ZH; Tien HF; Ou DL; Chien HF; Lin LI
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862120
[TBL] [Abstract][Full Text] [Related]
13. Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML.
Zhang B; Nguyen LXT; Zhao D; Frankhouser DE; Wang H; Hoang DH; Qiao J; Abundis C; Brehove M; Su YL; Feng Y; Stein A; Ghoda L; Dorrance A; Perrotti D; Chen Z; Han A; Pichiorri F; Jin J; Jovanovic-Talisman T; Caligiuri MA; Kuo CJ; Yoshimura A; Li L; Rockne RC; Kortylewski M; Zheng Y; Carlesso N; Kuo YH; Marcucci G
J Hematol Oncol; 2021 Aug; 14(1):122. PubMed ID: 34372909
[TBL] [Abstract][Full Text] [Related]
14. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
15. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
16. Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.
Bernot KM; Nemer JS; Santhanam R; Liu S; Zorko NA; Whitman SP; Dickerson KE; Zhang M; Yang X; McConnell KK; Ahmed EH; Muñoz MR; Siebenaler RF; Marcucci GG; Mundy-Bosse BL; Brook DL; Garman S; Dorrance AM; Zhang X; Zhang J; Lee RJ; Blum W; Caligiuri MA; Marcucci G
Blood; 2013 Nov; 122(23):3778-83. PubMed ID: 24085765
[TBL] [Abstract][Full Text] [Related]
17. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.
Gerloff D; Grundler R; Wurm AA; Bräuer-Hartmann D; Katzerke C; Hartmann JU; Madan V; Müller-Tidow C; Duyster J; Tenen DG; Niederwieser D; Behre G
Leukemia; 2015 Mar; 29(3):535-47. PubMed ID: 25092144
[TBL] [Abstract][Full Text] [Related]
18. Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.
Greenblatt S; Li L; Slape C; Nguyen B; Novak R; Duffield A; Huso D; Desiderio S; Borowitz MJ; Aplan P; Small D
Blood; 2012 Mar; 119(12):2883-94. PubMed ID: 22323452
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; Récher C
Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850
[TBL] [Abstract][Full Text] [Related]
20. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
